Aptorum Group Limited
Model RPIDD - Rapid Pathogen Identification and Detection Device Technology
RPIDD: Next-generation molecular-based diagnostics for unbiased" detection of any foreign pathogens (virus, bacteria, fungus, parasites) in infected patients using DNA/RNA; <24 hours turnaround time + cost effective, Blood sample and adaptable to others (including swab), Collaboration with technology from Nobel prize winner Sydney Brenner / A*Star Sg, Patented proprietary technology to prepare and enrich the pathogenic DNA/RNA and, deplete the background human host DNA simultaneously + AI analysis
Most popular related searches
antibiotic antimicrobial
blood sampling
blood culture
antibiotic resistant
antibiotic resistance
molecular diagnostic
dna bacteria
methicillin-resistant staphylococcus aureus
coronavirus
Based on internal tests, our technology can detect:
- A full range of DNA/RNA viruses, bacteria, fungi, parasites, including coronavirus such as COVID19
- Pathogen genes that cause antibiotic/antimicrobial resistance (e.g. MRSA)
- Previously unknown and novel mutated pathogens (e.g. new virus)
Based on internal tests, our technology can:
- REDUCE diagnosis time to 24 hours or less (vs avg. 3 5 days using blood culture)
- REDUCE cost of existing NGS-based diagnosis by more than 50%
- TARGET TO ACHIEVE analytical specificity >99.99% per pathogen + sensitivity >95%
- "Personalized Medicine" approach to infections allowing clinicians to prescribe suitable and targeted treatments at an early stage of admission of the patient